Table 5.
Nanotechnology-based treatment approaches for cancer in clinical trials.
| Nano-Chemotherapeutics | Type of Cancer | ClinicalTrials.gov Identifier |
|---|---|---|
| Carbon nanoparticles | Thyroid Cancer | NCT02724176 |
| Docetaxel-PNP | Advanced Solid Malignancies | NCT01103791 |
| Magnetic Nanoparticle Injection | Prostate Cancer | NCT02033447 |
| TKM-080301 | Colorectal Cancer with Hepatic Metastases | NCT01437007 |
| Pancreas Cancer with Hepatic Metastases | ||
| Gastric Cancer with Hepatic Metastases | ||
| ExoIntelliScore Prostate | Prostate Cancer | NCT02702856 |
| Dex2 | Non-small Cell Lung Cancer | NCT01159288 |
| ExoDx Prostate (IntelliScore) | Urologic Cancer | NCT04720599 |
| IGF-1R/AS ODN | Malignant Glioma of Brain | NCT01550523 |
| Etuximab nanoparticles | Colon Cancer, Colo-rectal Cancer | NCT03774680 |
| Quercetin-encapsulated PLGA-PEG nanoparticles |
Oral Cancer | NCT05456022 |
| BIND-014 | KRAS Positive Patients With Non-small Cell Lung Cancer | NCT02283320 |
| SN-38 liposome | Colorectal Cancer | NCT00311610 |
| Liposome Entrapped Docetaxel (LE-DT | Pancreatic Cancer | NCT01186731 |
| Pegylated Liposomal Doxorubicin | Ovarian Neoplasms | NCT02751918 |
| Rastuzumab and non-pegylated liposomal doxorubicin |
Breast Cancer | NCT02562378 |